SILO PHARMA, INC. Payments to Acquire Short-term Investments
SILO PHARMA, INC. (SILO) reported Payments to Acquire Short-term Investments of $37.60 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireShortTermInvestments · last filed 2026-08-13
- SILO PHARMA, INC. payments to acquire short-term investments for the quarter ending 2026-06-30 was $18.84K, a 15.13% decline year-over-year.
- SILO PHARMA, INC. payments to acquire short-term investments for the quarter ending 2026-03-31 was $18.76K, a 44.78% decline year-over-year.
- SILO PHARMA, INC. payments to acquire short-term investments for the quarter ending 2025-12-31 was $20.04K, a 46.78% decline year-over-year.
- SILO PHARMA, INC. payments to acquire short-term investments for the quarter ending 2025-09-30 was $20.50K, a 49.30% decline year-over-year.
- SILO PHARMA, INC. payments to acquire short-term investments for fiscal 2023 was $4.15M.
| Period end | Payments to Acquire Short-term Investments 3 month | Payments to Acquire Short-term Investments 6 month | Payments to Acquire Short-term Investments 9 month | Payments to Acquire Short-term Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $18.84K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $37.60K 10-Q · filed 2026-08-13 | $57.64K derived: sum of 3 quarters · filed 2026-08-13 | $78.14K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $18.76K 10-Q · filed 2026-05-14 | $38.80K derived: sum of 2 quarters · filed 2026-05-14 | $59.30K derived: sum of 3 quarters · filed 2026-05-14 | $81.50K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $20.04K derived: POS AM 12 month − 10-Q 9 month · filed 2026-04-14 | $40.54K derived: sum of 2 quarters · filed 2026-04-14 | $62.74K derived: sum of 3 quarters · filed 2026-08-13 | $96.71K POS AM · filed 2026-04-14 |
| 2025-09-30 | $20.50K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $42.70K derived: sum of 2 quarters · filed 2026-08-13 | $76.67K 10-Q · filed 2025-11-13 | $114.33K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $22.20K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $56.17K 10-Q · filed 2026-08-13 | $93.83K derived: sum of 3 quarters · filed 2026-08-13 | $134.26K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $33.97K 10-Q · filed 2026-05-14 | $71.63K derived: sum of 2 quarters · filed 2026-05-14 | $112.06K derived: sum of 3 quarters · filed 2026-05-14 | $156.72K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $37.66K derived: POS AM 12 month − 10-Q 9 month · filed 2026-04-14 | $78.09K derived: sum of 2 quarters · filed 2026-04-14 | $122.75K derived: sum of 3 quarters · filed 2026-04-14 | $175.54K POS AM · filed 2026-04-14 |
| 2024-09-30 | $40.43K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $85.09K derived: sum of 2 quarters · filed 2025-11-13 | $137.88K 10-Q · filed 2025-11-13 | -$6.18M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $44.66K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $97.45K 10-Q · filed 2025-08-13 | -$6.22M derived: sum of 3 quarters · filed 2025-08-13 | -$6.11M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $52.79K 10-Q · filed 2025-05-09 | -$6.27M derived: sum of 2 quarters · filed 2025-05-09 | -$6.15M derived: sum of 3 quarters · filed 2025-05-09 | -$1.81M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | -$6.32M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | -$6.21M derived: sum of 2 quarters · filed 2025-03-28 | -$1.86M derived: sum of 3 quarters · filed 2025-03-28 | $4.15M 10-K · filed 2025-03-28 |
| 2023-09-30 | $114.69K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $4.46M derived: sum of 2 quarters · filed 2024-11-12 | $10.47M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $4.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $10.35M 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $6.01M 10-Q · filed 2024-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |